Pulmonary arterial hypertension (PAH) is characterised by elevated pulmonary arterial pressures and obstructive lesions in the distal vasculature. As a result, the right ventricle is placed under excessive strain resulting in adaptive hypertrophy, progressing to maladaptive hypertrophy and failure. Women develop PAH more frequently than men. It is postulated that 17β-estradiol (E2) plays a role in disease pathogenesis and/or the E2 metabolic axis may be dysregulated in PAH. Growing evidence also implicates a role for ROS and oxidative stress in PAH, yet mechanisms linking these systems are elusive. We hypothesised that either E2 or the E2 metabolite, 16α-hydroxyestrone (16αOHE1), stimulates Nox-induced ROS generation and proliferative respo...
Pulmonary arterial hypertension (PAH) is clinically characterized by a progressive increase in pulmo...
Pulmonary arterial hypertension (PAH) is a complex and devastating disease with a poor long-term pro...
Abstract Dysfunctional bone morphogenetic protein receptor 2 (BMPR2) and endothelial nitric oxide sy...
Pulmonary arterial hypertension (PAH) is characterised by elevated pulmonary arterial pressures and ...
Women develop pulmonary arterial hypertension (PAH) more frequently than men. This may relate, in pa...
Estrogen and oxidative stress have been implicated in pulmonary arterial hypertension (PAH). Mechani...
Estrogen and oxidative stress have been implicated in pulmonary arterial hypertension (PAH). Mechani...
Pulmonary arterial hypertension (PAH) is a rapidly degenerating and devastating disease of increased...
Pulmonary arterial hypertension (PAH) is a sexually dimorphic disease with female predominance. This...
Serotonin (5HT) and NADPH oxidases (Nox) have been linked to the pathology of pulmonary arterial hyp...
Background: Women are at greater risk of developing pulmonary arterial hypertension, with estroge...
17β-Estradiol (E2) attenuates hypoxia-induced pulmonary hypertension (HPH) through estrogen receptor...
Regulation of arterial tone relies heavily on molecular crosstalk between endothelial and smooth mus...
Pulmonary arterial hypertension (PAH) is a progressive disease of the lung vasculature that involves...
Pulmonary arterial hypertension (PAH) is a devastating vasculopathy that predominates in women and h...
Pulmonary arterial hypertension (PAH) is clinically characterized by a progressive increase in pulmo...
Pulmonary arterial hypertension (PAH) is a complex and devastating disease with a poor long-term pro...
Abstract Dysfunctional bone morphogenetic protein receptor 2 (BMPR2) and endothelial nitric oxide sy...
Pulmonary arterial hypertension (PAH) is characterised by elevated pulmonary arterial pressures and ...
Women develop pulmonary arterial hypertension (PAH) more frequently than men. This may relate, in pa...
Estrogen and oxidative stress have been implicated in pulmonary arterial hypertension (PAH). Mechani...
Estrogen and oxidative stress have been implicated in pulmonary arterial hypertension (PAH). Mechani...
Pulmonary arterial hypertension (PAH) is a rapidly degenerating and devastating disease of increased...
Pulmonary arterial hypertension (PAH) is a sexually dimorphic disease with female predominance. This...
Serotonin (5HT) and NADPH oxidases (Nox) have been linked to the pathology of pulmonary arterial hyp...
Background: Women are at greater risk of developing pulmonary arterial hypertension, with estroge...
17β-Estradiol (E2) attenuates hypoxia-induced pulmonary hypertension (HPH) through estrogen receptor...
Regulation of arterial tone relies heavily on molecular crosstalk between endothelial and smooth mus...
Pulmonary arterial hypertension (PAH) is a progressive disease of the lung vasculature that involves...
Pulmonary arterial hypertension (PAH) is a devastating vasculopathy that predominates in women and h...
Pulmonary arterial hypertension (PAH) is clinically characterized by a progressive increase in pulmo...
Pulmonary arterial hypertension (PAH) is a complex and devastating disease with a poor long-term pro...
Abstract Dysfunctional bone morphogenetic protein receptor 2 (BMPR2) and endothelial nitric oxide sy...